louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04852432: Evaluation of the Efficacy of Oxygen Therapy and Clinical Feasibility of High Flow Nasal Cannula During Moderate and Deep Sedation in Pediatric Patients
Official title: Evaluation of the Efficacy of Oxygen Therapy and Clinical Feasibility of High Flow Nasal Cannula During Moderate and Deep Sedation in Pediatric Patients
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Pediatric Sedation
Lead sponsor: Seoul National University Hospital
Sponsor class: OTHER
First posted: 2021-04-21
Enrollment: 258
Sex: ALL
Maximum age (years): 17
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: The investigators evaluate the efficacy and safety of routine administration of oxygen during moderate or deep sedation in pediatric patients. In addition, in terms of efficacy and safety, oxygen administration via nasal prong and high flow nasal cannula will be compared.


Eligibility criteria: Inclusion Criteria:

* Children under the age of 18 who undergo moderate-deep sedation

Exclusion Criteria:

* Respiratory failure patients
* Increased intracranial pressure
* Recent massive nasal bleeding
* History of airway surgery
* Complete nasal obstruction
* Pulmonary hypertension
* Skull base fracture

Primary outcomes:
measure: Desaturation (≤95%)
timeFrame: through study completion, average 30 minutes
Secondary outcomes:
measure: Desaturation (≤90%)
timeFrame: through study completion, average 30 minutes
measure: CO2 value
timeFrame: through study completion, average 30 minutes
measure: Minimum saturation during sedation
timeFrame: through study completion, average 30 minutes
measure: Complications
timeFrame: through study completion, average 30 minutes
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Seoul National University Hospital
Study officials:
affiliation: Seoul National University Hospital
name: Jin-Tae Kim, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03245632: Epidemiological Characteristics and Treatment Protocol for Carbapenem-Resistant Klebsiella Pneumoniae in China
Official title: Epidemiological Characteristics and Treatment Protocol for Carbapenem-Resistant Klebsiella Pneumoniae in China
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Klebsiella Pneumoniae Infection
Lead sponsor: Sir Run Run Shaw Hospital
Sponsor class: OTHER
First posted: 2017-08-10
Enrollment: 800
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Consecutive patients admitted to all study hospitals and met the aboved eligibility

Brief summary: Klebsiella pneumoniae is one of the most common pathogens causing nosocomial infection. Recently, the emergency of Carbapenem-Resistant Klebsiella pneumoniae (CRKP) had cause the clinical therapy be very difficult. However, there is not much empirical data as to the prevalence, risk factors, characteristics, and the rationality of the current therapy for the CRKP infection. Thus, the study was aimed to investigate the epidemiology and risk factors, characteristics, and the rationality of the current therapy for the CRKP infection.

Detailed description: All the patients with culture positive of Klebsiella pneumoniae were screened and reported to the the clinical doctors and confirmed by them. And the clinical characteristics of the patiens, such as baseline data, outcomes etc, were recorded. Finially, to find the prevalence, risk factors, characteristics, and the rationality of the current therapy for the CRKP infection

Eligibility criteria: Inclusion Criteria:

* new confirmed noscomial infection of CRKP

Exclusion Criteria:

* Age\<18, or \>85 years old; Mixed infection of CRKP and other microbes

Primary outcomes:
measure: CRKP infection
timeFrame: 7 days
Secondary outcomes:
Other outcomes:
Locations:
city: Hangzhou
country: China
facility: Sir Run Run Shaw Hospital
state: Zhejiang
Study officials:
affiliation: Sir Run Run Shaw Hospital
name: Yun-song YU, Doctor
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03348332: Effect During Pregnancy and Intrapartum Health
Official title: Effect of Supervised Exercise During Pregnancy on Maternal and Newborn Intrapartum Health
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Pregnancy
Keywords: exercise
intrapartum
aerobic exercise
resistance exercise
wellbeing
Lead sponsor: Technical University of Madrid
Sponsor class: OTHER
First posted: 2017-11-20
Enrollment: 530
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Assessing the role of moderate exercise in newborn intrapartum variables have showed to be crucial not only on prescribing exercise safely, but also on understanding its impact on the prevention of some cardio-metabolic diseases after labor. Clarify this concept will be essential on reducing human risk for some chronic diseases through implementing supervised exercise programs during such a critical period.

Detailed description: The aim of this randomized controlled trial was to evaluate the effect of combined exercise (aerobic and strength exercise) on maternal and newborn intrapartum variables.

Eligibility criteria: Inclusion Criteria:

* Being healthy and able to exercise following American College of Obstetricians and Gynecologists (ACOG) guidelines.
* Being able to communicate in spanish
* Giving birth at Hospital Universitario de Puerta de Hierro (Majadahonda); Hospital Universitario Severo Ochoa (Leganés).

Exclusion Criteria:

* Multiparity
* Obstetrician complications
* Being interested in the study after 18 weeks
* Not being regular in physical exercise program
* Younger than 18 years old

Primary outcomes:
measure: Stage of labor
timeFrame: At the moment of delivery
Secondary outcomes:
measure: Maternal gestational weight gain
timeFrame: 40-42 weeks of gestation
measure: Glucose state
timeFrame: 24-26 weeks of gestation
measure: Blood pressure
timeFrame: 12, 20 and 34 weeks of gestation
measure: Gestational age
timeFrame: At the moment of delivery
measure: Birth weight
timeFrame: At the moment of delivery
Other outcomes:
Locations:
city: Madrid
country: Spain
facility: Universidad Politécnica de Madrid
Study officials:
affiliation: Universidad Politecnica de Madrid
name: Ruben Barakat Carballo, PhD
role: STUDY_DIRECTOR
affiliation: Universidad Politecnica de Madrid
name: María Perales Santaella, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00565032: Postpartum Thyroid Measures and Mood
Official title: Postpartum Thyroid Measures and Mood
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Postpartum Depression
Keywords: postpartum depression
thyroxine
thyroid antibodies
thyroid stimulating hormone
Edinburgh Postnatal Depression Scale (EPDS)
Lead sponsor: Oklahoma State University Center for Health Sciences
Sponsor class: OTHER
First posted: 2007-11-29
Enrollment: 75
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Subjects were patients from two Oklahoma State University Center for Health Sciences (OSUCHS) clinics in Tulsa, Oklahoma.

Brief summary: Women with abnormal serum thyroid antibody levels or abnormal TSH and/or T4 values are more likely than their normal counterparts to have higher scores on a common postpartum depression screening test.

Detailed description: This small pilot study was an attempt to corroborate a relationship between quantified mood and thyroid measures, using the numerical scores obtained from a common depression screen, the Edinburgh Postnatal Depression Scale (EPDS), as a continuum. Mood scores were compared with presence of thyroid autoantibodies and plasma concentrations of free T4 and TSH.

Eligibility criteria: Inclusion Criteria:

* Over 18 years of age
* In third trimester of pregnancy when recruited
* Negative for the following drugs detected by a urine drug screen:

  * Amphetamines
  * Barbiturates
  * Benzodiazepines
  * Cocaine
  * Opiates
  * Phencyclidine metabolites (PCP), and tricyclic antidepressants
  * Vaginal delivery
  * Screened negative for major depressive disorder on the Edinburgh Postnatal Depression Scale (EPDS) at her prenatal enrollment in the study
  * Receiving a score of 12 or lower out of a possible 30

Exclusion Criteria:

* Under age 18
* Positive for any of the following drugs:

  * Amphetamines
  * Barbiturates
  * Benzodiazepines
  * Cocaine
  * Opiates
  * Phencyclidine metabolites (PCP), and tricyclic antidepressants
  * Cesarean delivery
  * EPDS score over 12 at prenatal screening test

Primary outcomes:
measure: Numerical score on the Edinburgh Postnatal Depression Scale
timeFrame: seven weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Tulsa
country: United States
facility: Oklahoma State University Center for Health Sciences Houston Park Obstetrics Clinic
state: Oklahoma
Study officials:
affiliation: Philadelphia College of Osteopathic Medicine Georgia Campus
name: Gary H. Watson, PhD
role: STUDY_DIRECTOR
References:
citation: McCoy SJ, Beal JM, Payton ME, Stewart AL, DeMers AM, Watson GH. Postpartum thyroid measures and depressive symptomology: a pilot study. J Am Osteopath Assoc. 2008 Sep;108(9):503-7.
Clinical trial NCT02267252: Effects of Male-specific Antibodies on Sex Ratio
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Sperm Antibodies
Sex Ratio
Lead sponsor: Odense University Hospital
Sponsor class: OTHER
First posted: 2014-10-17
Enrollment: 30
Sex: MALE
Minimum age (years): 25
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Vasectomized men

Brief summary: Investigation of the ability of antibodies from vasectomized men in binding to Y-spermatozoa as a possible explanation of the lower sex ratio observed after microinsemination using epididymal sperm from vasectomized men.


Eligibility criteria: Inclusion Criteria:

* Vasectomized men

Exclusion Criteria:

* Men who do not understand the study information

Primary outcomes:
measure: Y/X sperm ratio after exposure to sperm-specific antibodies
timeFrame: Up to 28 months
Secondary outcomes:
Other outcomes:
Locations:
city: Odense
country: Denmark
facility: Fertility Clinic, Odense University Hospital
Study officials:
References:
Clinical trial NCT00547352: Study to Determine a Preference Between Sildenafil or Tadalafil Treatment for Problems Getting an Erection
Official title: Switching From Sildenafil Citrate to Tadalafil in Treatment of Erectile Dysfunction: Assessment of Treatment Preference
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Impotence
Lead sponsor: Eli Lilly and Company
Sponsor class: INDUSTRY
Collaborators: name: ICOS Corporation
First posted: 2007-10-22
Enrollment: 160
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Intervention model: CROSSOVER

Brief summary: To determine if men with problems getting and keeping an erection prefer treatment with tadalafil or sildenafil.


Eligibility criteria: Inclusion Criteria:

* History of erection problems
* Anticipate a monogamous female sexual relationship
* Abstain from other erection treatments throughout the study
* Currently use sildenafil

Exclusion Criteria:

* Other primary sexual disorders
* History of radical prostatectomy or other pelvic surgery that affected being able to have an erection
* History of penile implant or clinically significant penile deformity.
* Nitrate use
* Certain heart problems

Primary outcomes:
measure: Patient choice of drug at visit 5
timeFrame: 14-15 weeks
Secondary outcomes:
measure: PAIRS self-administered scale scores
timeFrame: 14-15 weeks
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon- Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Study officials:
affiliation: Eli Lilly and Company
name: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
role: STUDY_DIRECTOR
References:
Clinical trial NCT05289752: Direct Versus Indirect Pick up of the Locator Retentive Caps:(Within-patient Study)
Official title: Direct Versus Indirect Pick up of the Locator Retentive Caps for Two Implant-retained Mandibular Overdenture: Calibration of the Manufacturer Retentive Force and the Clinical Retention (Within-patient Study)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Prosthesis Durability
Lead sponsor: Mansoura University
Sponsor class: OTHER
First posted: 2022-03-21
Enrollment: 30
Sex: ALL
Minimum age (years): 40
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The purpose of this study will be to evaluate the effect of direct and indirect pick up of the locator retentive caps and compare the clinical results with those of the manufacturer retentive force.

Detailed description: Patient selection:

For this study, 30 patients were selected from the clinic of Prosthodontic Department, Faculty of Dentistry, Mansoura University.

According to pick up technique for the locator retentive caps, the overdentures will be classified into two groups as follows; Group1: The retentive caps will be picked up by indirect method on the cast then by the direct method Group2: The retentive caps will be picked up in the patient by the direct method first then by the indirect method.

For both groups, the clinical retention will be measured after using pink and blue retentive inserts respectively.

All implants were inserted using computer-guided implant surgery and conventional loading protocol was used.

Evaluation methods The clinical retention of each insert will be calibrated as regards the manufacturer's value.

Also, the laboratory retention will be assessed for the two groups and calibrated as regards the manufacturer's value.

Measurements will be done immediately, three and six months after each overdenture insertion.

Eligibility criteria: Inclusion Criteria:

* ● Free from any systemic disease that may interfere with the osseointegration of implants.

  * Patients will have completely edentulous maxilla and mandible for at least 6 months after the last extraction.
  * Patients will have normal maxilla mandibular relationships.
  * Mandibular arch with residual alveolar ridges covered with firmly attached mucosa.
  * The width of the mandibular ridge in the canine area will be sufficient for the installation of the implants in parallel anteroposterior and mesiodistal directions.

Exclusion Criteria:

* medically compromised patients smokers uncontrolled metabolic diseases ( diabetes mellitus ) uncooperative patients

Primary outcomes:
measure: measurement of overdenture retention
timeFrame: three months
Secondary outcomes:
measure: marginal bone loss
timeFrame: one year
measure: plaque index
timeFrame: one year
measure: gingival index
timeFrame: one year
measure: pocket depth
timeFrame: one year
Other outcomes:
Locations:
city: Mansoura
country: Egypt
facility: Christine Ibrahim
Study officials:
References:
Clinical trial NCT03159052: Efficacy and Safety of SHR3824 as Monotherapy in Subjects With Type 2 Diabetes
Official title: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Clinical Trial to Evaluate the Efficacy and Safety of SHR3824 as Monotherapy in in Chinese Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and Exercise
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE3
Conditions: Type 2 Diabetes Mellitus
Lead sponsor: Jiangsu HengRui Medicine Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2017-05-18
Enrollment: 450
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to obtain information on efficacy and safety of SHR3824 over 24 weeks and 52 weeks in Chinese patients with Type 2 Diabetes. This will be done by comparing the effect of SHR3824 to placebo when given in oral doses.


Eligibility criteria: Inclusion Criteria:

* Patients must have a diagnosis of type 2 diabetes mellitus;
* Patient either has not been previously treated with antihyperglycemic medication or has not been treated with antihyperglycemic in the last 8 weeks;
* FPG\<=15mmol/L;
* Hemoglobin A1c levels \>=7.0% and \<=10.5%;
* Body mass index (BMI) 19 to 35 kg/m2;

Exclusion Criteria:

* Type I diabetes mellitus, diabetes mellitus resulting from pancreatic disorder, or secondary diabetes mellitus (acromegaly, Cushing's syndrome, etc.);
* Past or current history of severe diabetic complications (proliferative diabetic retinopathy, stage III or later stage overt nephropathy, diabetic ketoacidosis, or serious diabetic neuropathy);
* Systolic blood pressure of ≥160 mmHg or diastolic blood pressure of ≥100 mmHg on the start or end day of the run-in period;
* History of myocardial infarction, unstable angina, or cerebrovascular disorder within 6 months before the start of the run-in period;
* Past or current history of malignant tumor;
* Past or current history of drug hypersensitivity such as shock and anaphylactoid symptoms;
* Pregnant women, lactating mothers, or women of childbearing potential;
* Any condition that subjects are assessed to be ineligible by the investigator (sub investigator).

Primary outcomes:
measure: Adjusted Mean Change in HbA1c Levels
timeFrame: Baseline to Week 24
measure: The number of volunteers with adverse events as a measure of safety
timeFrame: Baseline to Week 52
Secondary outcomes:
measure: Adjusted Mean Change in Fasting Plasma Glucose
timeFrame: Baseline to Week 24
Other outcomes:
Locations:
city: Beijing
country: China
facility: Chinese PLA General Hospital
Study officials:
References:
Clinical trial NCT01153152: Study of Pain Following Removal of Wisdom Teeth With Acute Pulpitis
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Pain
Keywords: wisdom teeth
acute pulpitis
extraction
pain
Pain Following Removal of Wisdom Teeth with Acute Pulpitis
Lead sponsor: Wuhan University
Sponsor class: OTHER
First posted: 2010-06-29
Sex: ALL
Minimum age (years): 20
Maximum age (years): 29
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: patients requiring surgical removal of a single upper wisdom tooth with acute pulpitis were included in this prospective study

Brief summary: The purpose of this study is to determine whether pulp chamber opening and drainage on wisdom teeth with acute pulpitis before the extraction could reduce postoperative pain so beneficial to patient.


Eligibility criteria: Inclusion Criteria:

* inclusion criteria of upper wisdom teeth for the two groups were: vertical eruption; being worthless to be restored; deep caries in the occlusion surface with acute pain; without caries or acute pulpitis in the adjacent second molar

Exclusion Criteria:

* systemic diseases, smokers, inflammation in oral cavity,with history of psychiatric illness,pregnant or lactating females

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Wuhan
country: China
facility: School and Hospital of Stomatology, Wuhan University
state: Hubei
Study officials:
References:
Clinical trial NCT02557152: The GentleWave Registry
Official title: The GentleWave Post-Market Registry
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Root Canal
Lead sponsor: Sonendo, Inc.
Sponsor class: INDUSTRY
First posted: 2015-09-23
Enrollment: 500
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Up to 500 subjects that have been treated with the Sonendo GentleWave System.

Brief summary: The purpose of this registry is to gain a real world perspective for the use and outcomes associated with the Sonendo® GentleWave System usage. The registry population includes up to 500 subjects that have been treated with the Sonendo GentleWave System at up to 25 clinical sites in the United States.

Detailed description: The purpose of this registry is to gain a real world perspective for the use and outcomes associated with the Sonendo® GentleWave System usage.

Up to 25 clinical sites in the United States. Up to 500 subjects that have been treated with the Sonendo GentleWave System. To assess outcomes for teeth treated with the GentleWave System in a commercial setting.

Eligibility criteria: Inclusion Criteria:

* One or more teeth treated with the Sonendo GentleWave System

Exclusion Criteria:

* Institutionalized patients or prisoners

Primary outcomes:
measure: Healing
timeFrame: 24 months
Secondary outcomes:
measure: Retreatment Rates
timeFrame: 24 months
Other outcomes:
Locations:
city: Encinitas
country: United States
facility: Randy Garland, DDS
state: California
city: Santa Ana
country: United States
facility: SC Endododontics
state: California
city: Whittier
country: United States
facility: Stacey Woo, DDS
state: California
Study officials:
affiliation: Sonendo, Inc.
name: Kim Bradbury
role: STUDY_DIRECTOR
References: